Guggenheim raised the firm’s price target on Tenet Healthcare (THC) to $238 from $221 and keeps a Buy rating on the shares, stating that the company “once again delivered a solid core quarter.” Tenet’s high-acuity strategy and approach to expectations still suggests more EBITDA, multiple expansion, and ultimately potential share price upside, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare Reports Strong Q3 2025 Results
- Strong Performance and Strategic Growth Drive Buy Rating for Tenet Healthcare
- Tenet Healthcare price target raised to $230 from $225 at BofA
- Morning Movers: UPS and PayPal jump following quarterly reports
- Tenet Healthcare reports Q3 adjusted EPS $3.70, consensus $3.35